Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
|Articles|March 15, 2018
- BioPharm International-03-15-2018
- Volume 2018 eBook
- Issue 1
Outsourcing: Does Focus Pay Off?
Author(s)Agnes Shanley
Research suggests that working with a single contract partner can reduce development time and improve economics.
Advertisement
Competitive pressures have led to explosive growth in demand for research and development (R&D) outsourcing, especially as smaller biopharma and pharmaceutical companies play a more prominent role in drug development. Pharmaceutical manufacturers, especially small- to mid-sized companies, are discovering that partnering more closely with one diversified contract company can reduce development time and cost.
View other articles in
Article Details
BioPharm International
eBook: Outsourcing Resources 2018
March 2018
Pages: 4–6
Citation
When referring to this article, please cite it as A. Shanley, “Outsourcing: Does Focus Pay Off?," BioPharm International Outsourcing Resources eBook (March 2018).
Articles in this issue
over 8 years ago
Quality Oversight During Sterile Filling Operationsover 8 years ago
Good Quality Agreements Support Compliance with CGMPover 8 years ago
Gaining Analytical Insight in the Development of Biologicsover 8 years ago
Contract Services Investment Updateover 8 years ago
Process Validation in Biologics Developmentover 8 years ago
Bigger is Better in Samsung's Approach to Biomanufacturingover 8 years ago
Choosing an Analytical Partner in Early Drug Developmentover 8 years ago
Avoiding Complete Response LettersAdvertisement
Related to this article
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Advertisement
Advertisement